Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$0.16
-6.6%
$16.01
$14.06
$63.00
$10.00M1.6264,763 shs1.05 million shs
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.07
-0.4%
$0.13
$0.04
$56.00
$738K1.691.32 million shs82,816 shs
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$8.50
$8.47
$3.10
$8.50
$26.35M1.0363,470 shsN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
$1.27
$0.85
$7.10
N/AN/AN/A87,682 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$1.33
-13.1%
$1.92
$0.87
$10.80
$6.38M0.478,399 shs12,038 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
0.00%0.00%-99.20%-99.12%-99.42%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00%-3.85%+18.21%-84.66%-99.87%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.00%0.00%0.00%0.00%0.00%
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
0.00%0.00%0.00%0.00%0.00%
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00%-11.33%-28.11%-39.48%+132,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
1.1503 of 5 stars
0.03.00.04.61.11.70.0
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.6806 of 5 stars
0.03.00.00.03.00.00.6
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/AN/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
2.50
Moderate BuyN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.00
N/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
0.00
N/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K1,000.25N/AN/A$0.08 per share1.94
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$310K85.00N/AN/A$8.97 per share0.95
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K9.64N/AN/A($6.58) per share-0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$219.00N/AN/AN/A-812.56%-207.31%8/11/2025 (Estimated)
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$380K$0.2929.31N/A248.35%-88.44%-64.15%N/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
-$126.35MN/A0.00N/AN/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36MN/A0.00N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)

Latest ODT, LMNL, HEPA, ORGS, and GLYC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$5.00-$4.00+$1.00-$0.04N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/A
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
1.92
1.92
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.02
2.78
2.78
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07

Institutional Ownership

CompanyInstitutional Ownership
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.66%
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
5064.53 million58.90 millionOptionable
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2010.93 million6.63 millionNo Data
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
2513.10 million3.04 millionNot Optionable
Odonate Therapeutics, Inc. stock logo
ODT
Odonate Therapeutics
14528.53 million14.58 millionNot Optionable
Orgenesis Inc. stock logo
ORGS
Orgenesis
1504.80 million4.53 millionNo Data

Recent News About These Companies

Orgenesis Delays Filing of Quarterly Report
Orgenesis secures $5M equity investment from Williamsburg Venture
Orgenesis Inc. Reports Q3 2024 Financial Results
Orgenesis Provides Third Quarter 2024 Business Update
Orgenesis Expands Board with Three New Appointments
Orgenesis commences trading on OTCQX Best Market
Orgenesis Commences Trading on OTCQX® Best Market
45O.SG,0P0001J8IU,0 (45O.SG)
Why Orgenesis (ORGS) Stock Is Down 23% Today
Orgenesis Inc.: Orgenesis Announces Reverse Stock Split
Orgenesis Approves 1-for-10 Reverse Stock Split
Orgenesis Announces Reverse Stock Split
Is Orgenesis Stock (ORGS) a Good Investment?
Orgenesis Advancing CD19 CAR T-cell Therapy Into Phase I/II Leukemia Trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

GlycoMimetics stock logo

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-6.63%)
Closing price 06/13/2025
Extended Trading
$0.16 0.00 (0.00%)
As of 06/13/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.07 0.00 (-0.44%)
As of 07/3/2025 12:55 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Liminal BioSciences stock logo

Liminal BioSciences NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Odonate Therapeutics stock logo

Odonate Therapeutics NASDAQ:ODT

Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$1.33 -0.20 (-13.07%)
As of 07/3/2025 12:46 PM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.